Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 6
2013 4
2014 5
2015 2
2016 15
2017 4
2018 5
2019 4
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Nocturnal temperature-controlled laminar airflow device for adults with severe allergic asthma: the LASER RCT.
Kapoor M, Storrar W, Balls L, Brown TP, Mansur A, Hedley E, Jones T, Roberts C, Shirkey B, Dutton S, Luengo-Fernandez R, Little M, Dewey A, Marshall S, Fogg C, Boughton K, Rahman N, Yu LM, Bradding P, Howarth P, Chauhan AJ. Kapoor M, et al. Health Technol Assess. 2019 Jun;23(29):1-140. doi: 10.3310/hta23290. Health Technol Assess. 2019. PMID: 31232684 Free PMC article. Clinical Trial.
Randomised controlled trials in severe asthma: selection by phenotype or stereotype.
Brown T, Jones T, Gove K, Barber C, Elliott S, Chauhan A, Howarth P; Wessex Severe Asthma Cohort (WSAC) team; Members of the Wessex Severe Asthma Cohort (WSAC) team:. Brown T, et al. Eur Respir J. 2018 Dec 13;52(6):1801444. doi: 10.1183/13993003.01444-2018. Print 2018 Dec. Eur Respir J. 2018. PMID: 30361247 Free article.
Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation.
Jevnikar Z, Östling J, Ax E, Calvén J, Thörn K, Israelsson E, Öberg L, Singhania A, Lau LCK, Wilson SJ, Ward JA, Chauhan A, Sousa AR, De Meulder B, Loza MJ, Baribaud F, Sterk PJ, Chung KF, Sun K, Guo Y, Adcock IM, Payne D, Dahlen B, Chanez P, Shaw DE, Krug N, Hohlfeld JM, Sandström T, Djukanovic R, James A, Hinks TSC, Howarth PH, Vaarala O, van Geest M, Olsson H; Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes study group. Jevnikar Z, et al. J Allergy Clin Immunol. 2019 Feb;143(2):577-590. doi: 10.1016/j.jaci.2018.05.026. Epub 2018 Jun 11. J Allergy Clin Immunol. 2019. PMID: 29902480 Free article.
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, Ulrik CS, Harrison T, Singh D, Chaudhuri R, Leaker B, McGarvey L, Siddiqui S, Wang M, Braddock M, Nordenmark LH, Cohen D, Parikh H, Colice G, Brightling CE; MESOS study investigators. Russell RJ, et al. Lancet Respir Med. 2018 Jul;6(7):499-510. doi: 10.1016/S2213-2600(18)30201-7. Epub 2018 May 21. Lancet Respir Med. 2018. PMID: 29793857 Clinical Trial.
42 results